BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 1
• 2
• 3
• 4
• 5
• 6
• 7
• 8
• 9
• 10
• 11
• 12
• 13
• 14
• 15
• 16
• 17
• 18
• 19
• 20
• 21
• 22
• 23
• 24
• 25
• 26
• 27
• 28
• 29
• 30
• 31

• 

  Drug Development

  COVID Update: Deaths Rising in Europe, Moderna vs. Pfizer and Vaccine Mandates

  In the face of Delta, the actual efficacy of the vaccines has come into question, while global cases and deaths from COVID-19 increased for the first time in two months, primarily in Europe.

  October 29, 2021

   · 

  5 min read

   · 

  Mark Terry
• 

  Drug Development

  “No Clear Response” Ends Early-Stage Daiichi Sankyo ADC Program

  Daiichi Sankyo announced the decision in its third quarter financial report this morning, where it said that the Phase I data yielded no clear responses in GIST patients.

  October 29, 2021

   · 

  2 min read

   · 

  Alex Keown
• 

  Drug Development

  Alnylam and AbbVie Each Reveal Influential Phase III Results

  After first reporting that its investigational RNAi drug vutrisiran hit its 9-month Phase III endpoints, Alnylam announced it continues to demonstrate positive results at the 18-month mark.

  October 29, 2021

   · 

  4 min read

   · 

  Alex Keown
• 

  Bio NC

  Clinical Catch-Up: October 25-29

  Yet another busy week for clinical trial news. Here’s a look.

  October 29, 2021

   · 

  12 min read

   · 

  Mark Terry
• 

  Lone Star Bio

  Potentially Predictive Genetic Link Could Help Identify Immune Checkpoint Blockade Therapy Responsive in Patients

  A new study was published this week and proposed a potential new biomarker for predetermining patient responsiveness to immune checkpoint blockade therapy.

  October 29, 2021

   · 

  2 min read

   · 

  Kaylei Whalen
• 

  Drug Development

  Kymera Study Validates IRAK4 as Viable Protein Degradation Target

  Kymera was able to demonstrate for the first time proof-of-biology ex vivo using whole blood from one of their KT-474 treated patient cohorts.

  October 29, 2021

   · 

  2 min read

   · 

  Maggie Chen
• 

  Job Trends

  Jaguar Gene Therapy, UCSF and Others Expand Innovation Capacity

  The 174,000 square-foot location will house a fully-equipped production plant to create its initial programs for Type 1 diabetes, a specific genetic cause of autism, galactosemia, and more.

  October 29, 2021

   · 

  3 min read

   · 

  Vanessa Doctor, RN
• 

  Business

  Pfizer’s Bourla on Drug Pricing: “We Have a Problem Here”

  Albert Bourla, chief executive officer of Pfizer, argued this week that politicians were approaching the problem of drug pricing the wrong way — as usual.

  October 29, 2021

   · 

  2 min read

   · 

  Mark Terry
• 

  Patients Maintain Disease Suppression After One Year on Gilead HIV Drug Biktarvy

  Gilead Sciences has one of the most robust HIV pipelines in the world. New real-world data from the ongoing BICSTaR study demonstrates benefits of HIV drug Biktarvy.

  October 29, 2021

   · 

  3 min read

   · 

  Alex Keown
• 

  FDA

  FDA Signs Off on Pfizer-BioNTech Vaccine for Kids 5 to 11

  The U.S. Food and Drug Administration granted Emergency Use Authorization (EUA) for the Pfizer-BioNTech vaccine for children ages 5 to 11.

  October 29, 2021

   · 

  3 min read

   · 

  Mark Terry